Cushing Syndrome Patients Face High Risk of Dangerous Blood Clots

Cushing syndrome, a complex endocrine disorder caused by prolonged exposure to excessive cortisol levels, is associated with numerous severe complications, including a significantly increased risk of thrombosis (blood clot formation). While hypercoagulability is a well-recognized feature of this condition, the specific mechanisms and overall prevalence of this thrombotic risk in patients with ACTH-dependent Cushing syndrome warrant comprehensive investigation. This distinction is crucial as ACTH-dependent forms often involve different etiologies and disease courses.

The review consistently identified a pronounced state of hypercoagulability in patients with ACTH-dependent Cushing syndrome, characterized by a multifaceted array of prothrombotic changes in their blood. Patients frequently exhibited significantly elevated levels of various procoagulant factors, such as Factor VIII, often showing a 2-fold increase compared to healthy control subjects, alongside reduced levels of crucial natural anticoagulants like Protein S, which could be decreased by up to 30%. Furthermore, markers indicative of impaired fibrinolysis (the process of clot breakdown), such as plasminogen activator inhibitor-1 (PAI-1), were often substantially elevated, suggesting a diminished capacity to dissolve existing clots. The most critical finding was that the overall risk of venous thromboembolism (VTE) in patients with ACTH-dependent Cushing syndrome was estimated to be 4-8 times higher than in the general population, with a reported incidence ranging from 2% to 10% depending on the specific study cohort and diagnostic criteria. This severe hypercoagulable state was observed both prior to and following surgical intervention, though it often showed some improvement after successful treatment of the underlying Cushing syndrome.